Department of Pathology
  Brigham and Women's Hospital
  A teaching Affliate of Harvard Medical School
Login Skip Navigation Links
  Skip Navigation Links
HomeExpand Home








Announcement
Submit new announcement
Shuji Ogino, M.D.,Ph.D.

   Associate Professor of Pathology
Academic Activities:
I conduct large-scale “Molecular Pathologic Epidemiology”, “Molecular Epidemiologic Pathology”, and “Epigenetic Epidemiology” research on colorectal cancer and neoplasia, and pancreatic cancer. “Molecular Pathologic Epidemiology” or “Molecular Epidemiologic Pathology” is a relatively new field of investigation, and we are among only a few research groups in the world using prospective cohort studies. Particularly, I am the first researcher who discovered an interactive effect of a tumoral biomarker (FASN, fatty acid synthase) and a lifestyle factor (body mass index, BMI) on patient outcome (J Clin Oncol 2008). I utilize the database of two prospective cohort studies, the Nurses’ Health Study (NHS, 121,700 women followed since 1976) and the Health Professionals Follow-up Study (HPFS, 51,500 men followed since 1986) in collaboration with Harvard School of Public Health (HSPH) and the Channing Laboratory of Brigham and Women’s Hospital. Both cohorts provide diet and lifestyle data over a 24 to 34-year period, genotyping data, data on incident cancers and other diseases, and long-term survival data as well as paraffin-embedded tissue specimens of colorectal cancer, adenoma and pancreatic cancer. I have been examining the relations between specific lifestyle, environmental or genetic factors, molecular alterations in these tumors, and clinical outcome of cohort participants. Analyses on the cohort samples are ongoing, and data are being published in a number of journals (including New Engl J Med 2007; J Natl Cancer Inst 2008; J Clin Oncol 2008, 2009; JAMA 2009; Gastroenterology 2009, etc.). Main themes of my research include epigenetics, epigenomics, cellular energy metabolism, inflammatory pathways and immune response. I have been characterizing the CpG island methylator phenotype (CIMP), a unique molecular phenotype in colorectal cancer. In 2006, I discovered “CIMP-low”, a unique phenotype in colorectal cancer which is associated with KRAS mutation (J Mol Diagn 2006). I have also discovered that LINE-1 methylation level is a strong predictor of patient survival (J Natl Cancer Inst 2008), and deficiency of dietary folate increases risks for LINE-1 hypomethylated cancer (Gut 2010). LINE-1 methylation can serve as a surrogate marker for genome-wide DNA methylation level. I also participate as an investigator in the multicenter trial, Cancer and Leukemia Group B (CALGB). In this group, I examine tumor biomarkers for prediction of clinical outcome of patients with colon cancer.
Office
44 Binney Street
JF-215C, Jimmy Fund building
Boston,MA 02115
Email1: shuji_ogino@dfci.harvard.edu
Education and Training:

Medical School - : University of Tokyo, Japan M.D.
Graduate School - : University of Tokyo, Japan Ph.D.
Residency 7/1/95 - 6/30/97 : Allegheny General Hospital
Residency 7/1/97 - 6/30/99 : University Hospitals of Cleveland
Fellowship 7/1/99 - 10/31/01 : University of Pennsylvania Medical Center

Clinical Specialties:
  • Molecular Diagnostics
Research Interests:
  • Colon cancer
  • Marker identification
  • Mutation
  • Epigenetics
  • Genetic alteration
  • Biotechnology
Publication:
  1. (Selected recent publications since 2005)
  2. ..
  3. Ogino S, Nosho K, Kirkner GJ, Shima K, Irahara N, Kure S, Chan AT, Engelman JA, Kraft P, Cantley LC, Giovannucci EL, Fuchs CS. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol 2008: In press.
  4. Ogino S, Nosho K, Meyerhardt JA, Kirkner GJ, Chan AT, Kawasaki T, Giovannucci EL, Loda M, Fuchs CS. A cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol 2008: In press.
  5. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, Giovannucci EL, Fuchs CS. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut: in press.
  6. Ogino S, Kirkner GJ, Nosho K, Irahara N, Kure S, Shima K, Hazra A, Chan AT, Dehari R, Giovannucci EL, Fuchs CS. Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin Cancer Res 2008: In press.
  7. Ogino S,* Goel A. Molecular classification and correlates in colorectal cancer [review]. J Mol Diagn 2008; 10: 13-27.
  8. Park DY, Sakamoto H, Kirley SD, Ogino S, Kawasaki T, Kwon E, Mino-Kenudson M, Lauwers GY, Chung DC, Rueda BR, Zukerberg LR. The Cables gene on chromosome 18q is silenced by promoter hypermethylation and allelic loss in human colorectal cancer. Am J Pathol 2007; 171: 1509-1519.
  9. Schernhammer ES, Giovannucci EL, Fuchs CS, Ogino S. A prospective study of dietary folate and vitamin B and colon cancer according to MSI and KRAS mutational status. Cancer Epidemiol Biomarkers Prev 2008: In press.
  10. Schernhammer ES, Ogino S, Fuchs CS. Folate intake and risk of colon cancer in relation to p53 alteration. Gastroenterology 2008: In press.
  11. Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Kirkner GJ, Fuchs CS, Ogino S.* IGFBP3 promoter methylation in colorectal cancer: relationship with microsatellite instability, CpG island methylator phenotype and p53. Neoplasia 2007; 9: 1091-1098.
  12. Ogino S,* Hazra A, Tranah GJ, Kirkner GJ, Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Meyerhardt JA, Hunter DJ, Fuchs CS. MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer. Carcinogenesis 2007; 28: 1985-1990.
  13. Nosho K, Kawasaki T, Chan AT, Ohnishi M, Suemoto Y, Kirkner GJ, Fuchs CS, Ogino S. Cyclin D1 is frequently overexpressed in microsatellite unstable colorectal cancer, independent of CpG island methylator phenotype. Histopathology 2008: in press.
  14. Firestein R, Bass AJ, Kim SY, Ian F. Dunn IF, Silver SJ, Guney I, Freed E, Ligon A, Vena N, Ogino S, Chheda M, Tamayo P, Finn S, Shrestha Y, Boehm JS, Jain S, Bojarski E, Barretina J, Chan JA, Baselga J, Tabernero J, Root DE, Fuchs C, Loda M, Shivdasani RA, Meyerson M, Hahn WC. CDK8 is a colorectal cancer oncogene that regulates beta-catenin. Nature 2008: in press.
  15. Ogino S,* Kawasaki T, Kirkner GJ, Suemoto Y, Meyerhardt JA, Fuchs CS. Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer. Gut 2007; 56: 1564-1571.
  16. Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Kirkner GJ, Dehari R, Meyerhardt JA, Fuchs CS, Ogino S*. Correlation of -catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype in colorectal cancer. Neoplasia 2007; 9: 569-577.
  17. Nosho K, Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, Zepf D, Yan L, Longtine JA, Fuchs CS, Ogino S. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia 2008; 10: 534-541.
  18. Firestein R, Blander G, Michan S, Oberdoerffer P, Ogino S, Campbell J, Bhimavarapu A, Luikenhuis S, de Cabo R, Fuchs C, Hahn WC, Guarente LP, Sinclair DA. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One 2008; 3: e2020.
  19. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. New Engl J Med 2007; 356: 2131-2142. (I am the sole pathologist in this study).
  20. Ogino S,* Kawasaki T, Kirkner GJ, Ohnishi M, Fuchs CS. 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high. BMC Cancer 2007; 7: 72 (electronic paper, 9 pages).
  21. Ogino S,* Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Kirkner GJ, Fuchs CS. LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Int J Cancer 2008; 122: 2767-2773.
  22. Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Glickman JN, Chan AT, Kirkner GJ, Mino-Kenudson M, Fuchs CS, Ogino S. Cyclooxygenase-2 overexpression is common in serrated and non-serrated colorectal adenoma, but uncommon in hyperplastic polyp and sessile serrated polyp/adenoma. BMC Cancer 2008; 8: 33.
  23. Ogino S,* Kawasaki T, Kirkner GJ, Kraft P, Loda M, Fuchs CS. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer using a large population-based sample. J Mol Diagn 2007; 9: 305-314.
  24. Ogino S,* Meyerhardt JA, Kawasaki T, Clark JW, Ryan DP, Kulke MH, Enzinger PC, Wolpin BM, Loda M, Fuchs CS. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch 2007; 450: 529-537.
  25. Kawasaki T, Ohnishi M, Nosho K, Suemoto Y, Kirkner GJ, Meyerhardt JA, Fuchs CS, Ogino S. CpG island methylator phenotype-low (CIMP-low) colorectal cancer shows not only few methylated CIMP-high-specific CpG islands, but also low-level methylation at individual loci. Mod Pathol 2008; 21: 245-255.
  26. Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, Liu Z, Yamamoto H, Loda M, Fuchs CS, Ogino S. WRN promoter methylation possibly connects mucinous differentiation, microsatellite instability and CpG island methylator phenotype in colorectal cancer. Mod Pathol 2008; 21: 150-158.
  27. Ogino S,* Kawasaki T, Ogawa A, Kirkner GJ, Loda M, Fuchs CS. Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype. Hum Pathol 2007; 38: 842-849.
  28. Ogino S,* Kawasaki T, Ogawa A, Kirkner GJ, Loda M, Fuchs CS. TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer. Hum Pathol 2007; 38: 614-620.
  29. Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Glickman JN, Chan AT, Kirkner GJ, Mino-Kenudson M, Fuchs CS, Ogino S. Cyclooxygenase-2 overexpression is common in serrated and non-serrated colorectal adenoma, but uncommon in hyperplastic polyp and sessile serrated polyp/adenoma. BMC Cancer 2008;8:33.
  30. Ogino S, Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Kirkner GJ, Fuchs CS. LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Int J Cancer 2008;122:2767-2773.
  31. Ogino S,* Kawasaki T, Ogawa A, Kirkner GJ, Loda M, Fuchs CS. Cytoplasmic localization of p27 (cyclin-dependent kinase inhibitor 1B/KIP1) in colorectal cancer: inverse correlations with nuclear p27 loss, microsatellite instability, and CpG island methylator phenotype. Hum Pathol 2007;38:585-592.
  32. Ogino S,* Gulley ML, den Dunnen JT, Wilson RB, Association for Molecular Pathology Training and Education Committee. Standard mutation nomenclature in molecular diagnostics: practical and educational challenges. J Mol Diagn 2007;9:1-6.
  33. Firestein R, Blander G, Michan S, Oberdoerffer P, Ogino S, Campbell J, Bhimavarapu A, Luikenhuis S, de Cabo R, Fuchs C, Hahn WC, Guarente LP, Sinclair DA. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS ONE 2008;3:e2020.
  34. Ogino S, Goel A. Molecular classification and correlates in colorectal cancer [review]. J Mol Diagn 2008;10:13-27.
  35. Ogino S,* Wilson RB, Gold B, Flodman P. Bayesian risk assessment in genetic testing for autosomal dominant disorders with age-dependent penetrance. J Genet Counsel 2007;16(1):29-39.
  36. Ogino S,* Kawasaki T, Kirkner GJ, Yamaji T, Loda M, Fuchs CS. Loss of nuclear p27 (CDKN1B / KIP1) in colorectal cancer is associated with microsatellite instability and CIMP. Mod Pathol 2007;20:15-22.
  37. Nosho K, Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, Zepf D, Yan L, Longtine JA, Fuchs CS, Ogino S. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia 2008;10:534-541.
  38. Firestein R, Bass AJ, Kim SY, Ian F. Dunn IF, Silver SJ, Guney I, Freed E, Ligon A, Vena N, Ogino S, Chheda M, Tamayo P, Finn S, Shrestha Y, Boehm JS, Jain S, Bojarski E, Barretina J, Chan JA, Baselga J, Tabernero J, Root DE, Fuchs C, Loda M, Shivdasani RA, Meyerson M, Hahn WC. CDK8 is a colorectal cancer oncogene that regulates ?-catenin. Nature 2008;455:547-551.
  39. Ogino S, Wilson RB. Bayesian analysis (chapter). In Molecular Pathology in Clinical Practice, edited by Leonard DG et al. Springer 2007.
  40. Ogino S,* Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn 2006; 8: 582-588.
  41. Nosho K, Kawasaki T, Chan AT, Ohnishi M, Suemoto Y, Kirkner GJ, Fuchs CS, Ogino S. Cyclin D1 is frequently overexpressed in microsatellite unstable colorectal cancer, independent of CpG island methylator phenotype. Histopathology 2008;53:588-598.
  42. Schernhammer ES, Ogino S, Fuchs CS. Folate intake and risk of colon cancer in relation to p53 alteration. Gastroenterology 2008;135:770-780.
  43. Priolo C, Tang D, Brahamandan M, Benassi B, Sicinska E, Ogino S, Farsetti A, Porrello A, Finn S, Zimmermann J, Febbo P, Loda M. The isopeptidase USP2a protects human prostate cancer from apoptosis. Cancer Res 2006; 66(17): 8625-8632.
  44. Ogino S,* Kawasaki T, Kirkner GJ, Ogawa A, Dorfman I, Loda M, Fuchs CS. Down-regulation of p21 (CDKN1A / CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer. J Pathol 2006; 210: 147-154.
  45. Schernhammer ES, Giovannucci EL, Fuchs CS, Ogino S. A prospective study of dietary folate and vitamin B and colon cancer according to MSI and KRAS mutational status. Cancer Epidemiol Biomarkers Prev 2008;17:2895-2898.
  46. Ogino S, Kirkner GJ, Nosho K, Irahara N, Kure S, Shima K, Hazra A, Chan AT, Dehari R, Giovannucci EL, Fuchs CS. Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin Cancer Res 2008;14:8221-8227.
  47. Ogino S,* Odze RD, Kawasaki T, Brahmandam M, Kirkner GJ, Laird PW, Loda M, Fuchs CS. Correlations of pathologic features with CpG island methylator phenotype (CIMP) by quantitative DNA methylation analysis in colorectal carcinoma. Am J Surg Pathol 2006; 30(9): 1175-1183.
  48. Ogino S,* Brahmandam M, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. Epigenetic profiling of synchronous colorectal neoplasias by quantitative DNA methylation analysis. Mod Pathol 2006; 19: 1083-1090.
  49. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Chan AT, Schernhammer ES, Giovannucci EL, Fuchs CS. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst 2008;100:1734-1738
  50. Nosho K, Irahara N, Shima K, Kure S, Kirkner GJ, Schernhammer ES, Hazra A, Hunter DJ, Quackenbush J, Spiegelman D, Giovannucci EL, Fuchs CS, Ogino S. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS ONE 2008;3:e3698.
  51. Ogino S,* Brahmandam M, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Neoplasia 2006; 8: 458-464.
  52. Ogino S,* Kawasaki T, Brahmandam M, Cantor M, Kirkner GJ, Spiegelman D, Makrigiorgos GM, Weisenberger DJ, Laird PW, Loda M, Fuchs CS. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn 2006; 8: 209-217.
  53. Ogino S, Nosho K, Meyerhardt JA, Kirkner GJ, Chan AT, Kawasaki T, Giovannucci EL, Loda M, Fuchs CS. Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol 2008;26:5713-5720.
  54. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, Giovannucci EL, Fuchs CS. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009;58:90-96.
  55. Ogino S,* Brahmandam M, Cantor M, Namgyal C, Kawasaki T, Kirkner G, Meyerhardt JA, Loda M, Fuchs CS. Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol 2006; 19: 59-68.
  56. Ogino S,* Cantor M, Kawasaki T, Brahmandam M, Kirkner GJ, Weisenberger DJ, Campan M, Laird PW, Loda M, Fuchs CS. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut 2006; 55: 1000-1006.
  57. Monzon FA, Ogino S, Hammond ME, Halling KC, Bloom K, Nikiforova MN. The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer [review]. Arch Pathol Lab Med 2009;133:1600-1606.
  58. The Methylation Working Group of the Association for Molecular Pathology (AMP) Clinical Practice Committee (Contributing members of the AMP Methylation Working Group: Sepulveda AR, Jones D, Ogino S, Samowitz W, Gulley ML, Edwards R, Levenson V, Pratt VM, Yang B, Nafa K, Yan L, Vitazka P). CpG Methylation Analysis - Current Status of Clinical Assays and Potential Applications in Molecular Diagnostics: A Report of the Association for Molecular Pathology [review]. J Mol Diagn 2009;11:266-278.
  59. Ogino S,* Meyerhardt JA, Cantor M, Brahmandam M, Clark JW, Namgyal C, Kawasaki T, Kinsella K, Michelini AL, Enzinger PC, Kulke MH, Ryan DP, Loda M, Fuchs CS. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res 2005; 11(18): 6650-6656.
  60. Giovannucci E, Ogino S. DNA methylation, field effects, and colorectal cancer [editorial]. J Natl Cancer Inst 2005; 97(18): 1317-1319.
  61. Nosho K, Shima K, Kure S, Irahara N, Baba Y, Chen L, Kirkner GJ, Fuchs CS, Ogino S. JC virus T-antigen in colorectal cancer Is associated with p53 expression and chromosomal instability, independent of CpG island methylator phenotype. Neoplasia 2009;11:87-95.
  62. Ogino S, Nosho K, Kirkner GJ, Shima K, Irahara N, Kure S, Chan AT, Engelman JA, Kraft P, Cantley LC, Giovannucci EL, Fuchs CS. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol 2009;27:1477-1484.
  63. Ogino S, Shima K, Baba Y, Nosho K, Irahara N, Kure S, Chen L, Toyoda S, Kirkner GJ, Wang YL, Giovannucci EL, Fuchs CS. Colorectal cancer expression of peroxisome proliferator-activated receptor-? (PPARG, PPARgamma) is associated with good prognosisis. Gastroenterology 2009;136:1242-1250.
  64. a Y, Nosho K, Shima K, Irahara N, Kure S, Toyoda S, Kirkner GJ, Goel A, Fuchs CS, Ogino S. Aurora-A expression is independently associated with chromosomal instability in colorectal cancer. Neoplasia 2009;11:418-425.
  65. Ogino S, Nosho K, Irahara N, Shima K, Baba Y, Kirkner GJ, Meyerhardt JA, Fuchs CS. A cohort study of p27 localization in colon cancer, body mass index and patient survival. Cancer Epidemiol Biomarkers Prev 2009;18:1849-1858.
  66. Nosho K, Shima K, Irahara N, Kure S, Baba Y, Kirkner GJ, Chen L, Gokhale S, Hazra A, Spiegelman D, Giovannucci EL, Jaenisch R, Fuchs CS, Ogino S. DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer. Clin Cancer Res 2009;15:3663-3671.
  67. Ogino S, Nosho K, Irahara N, Kure S, Shima K, Baba Y, Toyoda S, Chen L, Giovannucci EL, Meyerhardt JA, Fuchs CS. A cohort study of cyclin D1 expression and prognosis in 602 colon cancer cases. Clin Cancer Res 2009;15:4431-4438.
  68. Nosho K, Shima K, Irahara N, Kure S, Firestein R, Baba Y, Toyoda S, Chen L, Hazra A, Giovannucci EL, Fuchs CS, Ogino S. SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Mod Pathol 2009;22:922-932.
  69. Baba Y, Nosho K, Shima K, Freed E, Irahara N, Philips J, Meyerhardt JA, Hornick JL, Shivdasani RA, Fuchs CS, Ogino S. Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer. Clin Cancer Res 2009;15:4665-4673.
  70. Souglakos J, Philips J, Wang R, Marwah S, Silver M, Tzardi M, Silver J, Ogino S, Hooshmand S, Kwak E, Freed E, Meyerhardt JA, Saridaki Z, Georgoulias V, Finkelstein D, Fuchs CS, Kulke MH, Shivdasani RA. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Brit J Cancer 2009:101:465-472.
  71. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA – J Am Med Assoc 2009;302:649-658. (I am the sole pathologist in this study)
  72. Ogino S, Nosho K, Baba Y, Kure S, Shima K, Irahara N, Toyoda S, Chen L, Kirkner GJ, Wolpin BM, Chan AT, Giovannucci EL, Fuchs CS. A cohort study of STMN1 expression in colorectal cancer: body mass index and prognosis. Am J Gastroenterol 2009;104:2047-56.
  73. Ogino S, Nosho K, Irahara N, Shima K, Baba Y, Kirkner GJ, Meyerhardt JA, Fuchs CS. Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers. J Clin Oncol 2009;27:4591-4598.
  74. Meyerhardt JA, Ogino S, Kirkner GJ, Chan AT, Wolpin B, Ng K, Nosho K, Shima K, Giovannucci EL, Loda M, Fuchs CS. Interaction of molecular markers and physical activity on mortality in patients with colon cancer. Clin Cancer Res 2009;15:5931-5936.
  75. Ogino S, Nosho K, Shima K, Baba Y, Irahara N, Kirkner GJ, Hazra A, De Vivo I, Giovannucci EL, Meyerhardt JA, Fuchs CS. p21 expression in colon cancer and modifying effects of patient age and body mass index on prognosis. Cancer Epidemiol Biomarkers Prev 2009;18:2513-2521.
  76. Worthley DL, Le Leu RK, Whitehall V, Conlon M, Christophersen C, Belobrajdic D, Mallitt K, Hu Y, Irahara N, Ogino S, Leggett BA, Young GP. A human, double-blind, placebo-controlled, cross-over trial of prebiotic, probiotic and synbiotic supplementation: effects on luminal, inflammatory, epigenetic and epithelial biomarkers of colorectal cancer. Am J Clin Nutr 2009;90:578-586.
  77. Ogino S, Nosho K, Irahara N, Meyerhardt JA, Baba Y, Shima K, Glickman JN, Ferrone CR, Mino-Kenudson M, Tanaka N, Dranoff G, Giovannucci EL, Fuchs CS. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res 2009;15:6412-6420.
  78. Kure S, Nosho K, Baba Y, Irahara N, Shima K, Ng K, Meyerhardt JA, Giovannucci EL, Fuchs CS, Ogino S. Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer. Cancer Epidemiol Biomarkers Prev 2009;18:2765-2772.
  79. Nosho K, Kure S, Irahara N, Shima K, Baba Y, Spiegelman D, Meyerhardt JA, Giovannucci EL, Fuchs CS, Ogino S. A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers. Gastroenterology 2009;137:1609-1620.
  80. Ogino S, Meyerhardt JA, Irahara N, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittom R, Hantel A, Benson III AB, Goldberg RM, Bertagnolli MM, Fuchs CS: for the Cancer and Leukemia Group B, North Central Cancer Treatment Group, Canadian Cancer Society Research Institute, Southwest Oncology Group. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res 2009;15:7322-7329.
  81. Meyerhardt JA, Giovannucci EL, Ogino S, Kirkner GJ, Chan AT, Willett W, Fuchs CS. Physical activity and male colorectal cancer survival. Arch Int Med 2009;169:2102-2108.
  82. Schernhammer ES, Giovannucci E, Kawasaki T, Rosner B, Fuchs CS, Ogino S. Dietary folate, alcohol, and B vitamins in relation to LINE-1 hypomethylation in colon cancer. Gut 2010: in press (published online).
  83. Ogino S, Nosho K, Irahara N, Shima K, Baba Y, Kirkner GJ, Mino-Kenudson M, Giovannucci EL, Meyerhardt JA, Fuchs CS. Negative lymph node count is associated with survival of colorectal cancer patients, independent of tumoral molecular alterations and lymphocytic reaction. Am J Gastroenterol 2010: in press (published online).
  84. Firestein R, Shima K, Nosho K, Irahara N, Baba Y, Bojarski E, Giovannucci EL, Hahn WC, Fuchs CS, Ogino S. CDK8 expression in 470 colorectal cancers in relation to ?-catenin activation, other molecular alterations and patient survival. Int J Cancer 2010: in press (published online).
  85. Irahara N, Nosho K, Baba Y, Shima K, Lindeman NI, Hazra A, Schernhammer ES, Hunter DJ, Fuchs CS, Ogino S. Precision of Pyrosequencing assay to measure LINE-1 methylation in colon cancer, normal colonic mucosa and peripheral blood cells. J Mol Diagn 2010: in press.
  86. Hazra A, Fuchs CS, Kawasaki T, Kirkner GJ, Hunter DJ, Ogino S. Germline polymorphisms in the one-carbon metabolism pathway and DNA methylation in colorectal cancer. Cancer Causes Control 2010: in press (published online).
  87. Irahara N, Baba Y, Nosho K, Shima K, Yan L, Dias-Santagata D, Iafrate AJ, Fuchs CS, Haigis KM, Ogino S. NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol 2010: in press.
  88. Worthley DL, Whitehall VLJ, Buttenshaw RL, Irahara N, Greco SA, Ramsnes I, Mallitt K, Le Leu RK, Winter J, Hu Y, Ogino S, Young GP, Leggett BA. DNA methylation within the normal colorectal mucosa is associated with pathway specific predisposition to cancer. Oncogene 2010: in press.
  89. Baba Y, Nosho K, Shima K, Irahara N, Chan AT, Meyerhardt JA, Chung DC, Giovannucci EL, Fuchs CS, Ogino S. HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. Am J Pathol 2010: in press.
  90. Baba Y, Nosho K, Shima K, Goessling W, Chan AT, Ng K, Chan JA, Giovannucci EL, Fuchs CS, Ogino S. PTGER2 Overexpression in Colorectal Cancer is Associated with Microsatellite Instability, Independent of CpG Island Methylator Phenotype. Cancer Epidemiol Biomarkers Prev 2010: in press.
Copyright 2008 - 2010, BWH Pathology, All rights reserved.